These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

492 related items for PubMed ID: 27411054

  • 1. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.
    Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M, Bosenberg M, Choi JN.
    JAMA Dermatol; 2016 Oct 01; 152(10):1128-1136. PubMed ID: 27411054
    [Abstract] [Full Text] [Related]

  • 2. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.
    Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F, Sznol M, Petrylak DP, Fischbach N, Goldberg SB, Decker RH, Stamatouli AM, Hafez N, Glusac EJ, Tomayko MM, Leventhal JS.
    J Am Acad Dermatol; 2018 Dec 01; 79(6):1081-1088. PubMed ID: 30025829
    [Abstract] [Full Text] [Related]

  • 3. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy.
    Schaberg KB, Novoa RA, Wakelee HA, Kim J, Cheung C, Srinivas S, Kwong BY.
    J Cutan Pathol; 2016 Apr 01; 43(4):339-46. PubMed ID: 26762844
    [Abstract] [Full Text] [Related]

  • 4. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
    Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S, Carlino MS, Kefford R, Fernandez-Penas P.
    J Am Acad Dermatol; 2016 Mar 01; 74(3):455-61.e1. PubMed ID: 26793994
    [Abstract] [Full Text] [Related]

  • 5. Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer.
    Rivera N, Boada A, Bielsa MI, Fernández-Figueras MT, Carcereny E, Moran MT, Ferrándiz C.
    JAMA Dermatol; 2017 Nov 01; 153(11):1162-1165. PubMed ID: 28700789
    [Abstract] [Full Text] [Related]

  • 6. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.
    Tetzlaff MT, Nagarajan P, Chon S, Huen A, Diab A, Omar P, Aung PP, Torres-Cabala CA, Mays SR, Prieto VG, Curry JL.
    Am J Dermatopathol; 2017 Feb 01; 39(2):121-129. PubMed ID: 28134729
    [Abstract] [Full Text] [Related]

  • 7. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
    Min Lee CK, Li S, Tran DC, Zhu GA, Kim J, Kwong BY, Chang ALS.
    J Am Acad Dermatol; 2018 Dec 01; 79(6):1047-1052. PubMed ID: 29857011
    [Abstract] [Full Text] [Related]

  • 8. Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings.
    Sibaud V, Eid C, Belum VR, Combemale P, Barres B, Lamant L, Mourey L, Gomez-Roca C, Estilo CL, Motzer R, Vigarios E, Lacouture ME.
    J Eur Acad Dermatol Venereol; 2017 Oct 01; 31(10):e464-e469. PubMed ID: 28419570
    [No Abstract] [Full Text] [Related]

  • 9. Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Death-1 (anti-PD-1) Therapy With or Without Ipilimumab.
    Chou S, Hwang SJ, Carlos G, Wakade D, Fernandez-Penas P.
    Am J Dermatopathol; 2017 Jan 01; 39(1):23-27. PubMed ID: 28045749
    [Abstract] [Full Text] [Related]

  • 10. Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review.
    Obara K, Masuzawa M, Amoh Y.
    J Dermatol; 2018 May 01; 45(5):587-591. PubMed ID: 29352490
    [Abstract] [Full Text] [Related]

  • 11. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.
    Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS.
    J Am Acad Dermatol; 2019 Apr 01; 80(4):990-997. PubMed ID: 30399387
    [Abstract] [Full Text] [Related]

  • 12. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
    Wang LL, Patel G, Chiesa-Fuxench ZC, McGettigan S, Schuchter L, Mitchell TC, Ming ME, Chu EY.
    JAMA Dermatol; 2018 Sep 01; 154(9):1057-1061. PubMed ID: 30027278
    [Abstract] [Full Text] [Related]

  • 13. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
    Remon J, Chaput N, Planchard D.
    Curr Opin Oncol; 2016 Mar 01; 28(2):122-9. PubMed ID: 26756384
    [Abstract] [Full Text] [Related]

  • 14. Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
    Marques-Piubelli ML, Tetzlaff MT, Nagarajan P, Duke TC, Glitza Oliva IC, Ledesma DA, Aung PP, Torres-Cabala CA, Wistuba II, Prieto VG, Nelson KC, Curry JL.
    J Cutan Pathol; 2020 Oct 01; 47(10):954-959. PubMed ID: 32394425
    [Abstract] [Full Text] [Related]

  • 15. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy.
    Joseph RW, Cappel M, Goedjen B, Gordon M, Kirsch B, Gilstrap C, Bagaria S, Jambusaria-Pahlajani A.
    Cancer Immunol Res; 2015 Jan 01; 3(1):18-22. PubMed ID: 25287118
    [Abstract] [Full Text] [Related]

  • 16. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
    Marano AL, Clarke JM, Morse MA, Shah A, Barrow W, Selim MA, Hall RP, Cardones AR.
    Br J Dermatol; 2019 Sep 01; 181(3):580-583. PubMed ID: 30244487
    [Abstract] [Full Text] [Related]

  • 17. Digital ulcerative lichenoid dermatitis in a patient receiving anti-PD-1 therapy.
    Martínez-Doménech Á, García-Legaz Martínez M, Magdaleno-Tapial J, Valenzuela-Oñate C, Pérez-Pastor G, Pérez-Ferriols A.
    Dermatol Online J; 2019 Sep 15; 25(9):. PubMed ID: 31738845
    [Abstract] [Full Text] [Related]

  • 18. Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management.
    Shen J, Chang J, Mendenhall M, Cherry G, Goldman JW, Kulkarni RP.
    Ther Adv Med Oncol; 2018 Sep 15; 10():1758834017751634. PubMed ID: 29383039
    [Abstract] [Full Text] [Related]

  • 19. Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report.
    Esfahani K, Henderson Berg MH, Zargham H, Billick R, Pehr K, Redpath M, Roshdy O, Miller WH.
    J Immunother Cancer; 2021 Mar 15; 9(3):. PubMed ID: 33771890
    [Abstract] [Full Text] [Related]

  • 20. PD-1 inhibitor-associated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation-Report of 4 cases.
    Chou S, Zhao C, Hwang SJE, Fernandez-Penas P.
    J Cutan Pathol; 2017 Oct 15; 44(10):851-856. PubMed ID: 28753231
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.